Sirtex Medical Ltd., of Sydney, highlighted the publication of results from the SIRFLOX study, a test of SIR-Spheres Y-90 resin microspheres, published online in the Journal of Clinical Oncology. In the primary endpoint of the study, patients with nonresectable liver-dominant or liver-only colorectal cancer who received FOLFOX-based first-line chemotherapy alone had a median progression-free survival (PFS) at any site of 10.2 months vs. 10.7 months in those that received chemotherapy plus SIR-Spheres.